Last 5.90 INR
Change Today -0.31 / -4.99%
Volume 300.0
ARL On Other Exchanges
Symbol
Exchange
Mumbai
As of 6:00 AM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

auro laboratories ltd (ARL) Snapshot

Open
5.90
Previous Close
6.21
Day High
5.90
Day Low
5.90
52 Week High
07/12/13 - 8.30
52 Week Low
10/30/13 - 5.28
Market Cap
36.8M
Average Volume 10 Days
508.0
EPS TTM
0.33
Shares Outstanding
6.2M
EX-Date
--
P/E TM
17.9x
Dividend
--
Dividend Yield
--
Current Stock Chart for AURO LABORATORIES LTD (ARL)

Related News

No related news articles were found.

auro laboratories ltd (ARL) Related Businessweek News

No Related Businessweek News Found

auro laboratories ltd (ARL) Details

Auro Laboratories Limited is engaged in manufacturing and selling active pharmaceutical ingredients (APIs), intermediates, and generic formulations in India. It offers APIs for various drugs comprising antihistamine, muscle relaxant, diuretic, iron deficiency, anti diabetic, anti fungal, anti ulcer, iodine supplement, anti malaria, analgesics, antacids, and anti inflammatory, as well as for other products, including potassium iodide, sodium iodide, and microcrystalline cellulose. The company’s intermediates product line comprises glibenclamde sulphonamide for use in the API glibenclamide; cis-bramo benzoate and cls-tosylate, which is used in the API ketoconazol; 3,4,5 - trimethoxy benzoic acid; 2-ethoxy benzoic acid for use in the API sildenafil citrate; and 5-bromo phthalide that is used in the API citalopram. In addition, it undertakes custom manufacturing for agrochemicals, intermediates, and APIs, as well as provides specialty chemicals products. The company also exports its products to Southeast Asia, the Middle East, and various European countries. Auro Laboratories Limited was incorporated in 1989 and is based in Mumbai, India.

Founded in 1989

auro laboratories ltd (ARL) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

auro laboratories ltd (ARL) Key Developments

Auro Laboratories Ltd. Announces Audited Standalone Earnings Results for the Fourth Quarter and Year Ended March 31, 2014

Auro Laboratories Ltd. announced audited standalone earnings results for the fourth quarter and year ended March 31, 2014. For the quarter, the company reported net sales of INR 83.913 million against INR 11.865 million for the same period last year. Profit from before interest was INR 4.699 million against INR 4.405 million a year ago. Profit from ordinary activities before tax was INR 2.088 million against loss form ordinary activities before tax of INR 0.042 million a year ago. Net profit for the period was INR 2.088 million against net loss for the period of INR 0.042 million a year ago. Basic and diluted earnings per share before and after extraordinary items were INR 0.33 against basic and diluted earnings per share before and after extraordinary items of INR 0.01 a year ago. For the year, the company reported net sales of INR 361.332 million against INR 474.133 million for the same period last year. Profit from before interest was INR 19.041 million against INR 23.714 million a year ago. Profit from ordinary activities before tax was INR 6.790 million against INR 7.665 million a year ago. Net profit for the period was INR 5.790 million against INR 7.665 million a year ago. Basic and diluted earnings per share before and after extraordinary items was INR 0.83 against INR 1.24 a year ago.

Auro Laboratories Ltd., Board Meeting, May 30, 2014

Auro Laboratories Ltd., Board Meeting, May 30, 2014. Agenda: To approve quarterly results.

Auro Laboratories Ltd. Reports Audited Earnings Results for the Third Quarter and Nine Months Ended December 31, 2013

Auro Laboratories Ltd. reported audited earnings results for the third quarter and nine months ended December 31, 2013. For the quarter, net sales /income from operations was INR 81.171 million compared to INR 109.201 million a year ago. Profit before interest was INR 4.423 million compared to INR 6.471 million a year ago. Profit from ordinary activities before tax and net profit was INR 0.886 million or INR 0.14 per basic and diluted share before and after extraordinary items compared to INR 2.366 million or INR 0.38 per basic and diluted share before and after extraordinary items a year ago. For the nine months, net sales /income from operations was INR 277.419 million compared to INR 284.341 million a year ago. Profit before interest was INR 14.342 million compared to INR 15.929 million a year ago. Profit from ordinary activities before tax and net profit was INR 3.702 million or INR 0.59 per basic and diluted share compared to INR 4.415 million or INR 0.71 per basic and diluted share before and after extraordinary items a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARL:IN 5.90 INR -0.31

ARL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ARL.
View Industry Companies
 

Industry Analysis

ARL

Industry Average

Valuation ARL Industry Range
Price/Earnings 6.7x
Price/Sales 0.1x
Price/Book 0.6x
Price/Cash Flow 2.9x
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AURO LABORATORIES LTD, please visit www.aurolabs.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.